<DOC>
	<DOCNO>NCT02174263</DOCNO>
	<brief_summary>This phase II trial study well tocilizumab work treat chronic graft-versus-host disease ( GVHD ) patient respond treatment least two prior therapy . Tocilizumab block protein stimulate body 's immune system . By block protein , investigator may reduce symptom chronic GVHD .</brief_summary>
	<brief_title>Tocilizumab Chronic Graft-versus-Host Disease Treatment</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I. Efficacy determine proportion patient failure free survival ( FFS ) 6 month . SECONDARY OBJECTIVES : I . Patients achieve complete response ( CR ) partial response ( PR ) 6 month base clinician judge response . II . Patients achieve CR PR objective response measure 6 month . III . Failure-free survival ( FFS ) 1 year . IV . Change steroid dose enrollment 6 month ( mo ) . TERTIARY OBJECTIVES : I. Biologic study do determine possible mechanisms response . OUTLINE : Patients receive tocilizumab intravenously ( IV ) 1 hour every 2 week 12 week ( week 1 , 3 , 5 , 7 , 9 , 11 ) every 4 week 12 week ( week 13 , 17 , 21 ) . After completion study treatment , patient follow 3 6 month .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Subject moderate severe overlap chronic ( c ) GVHD accord National Institutes Health ( NIH ) criterion Active cGVHD despite treatment least two immunosuppressive treatment ( include GVHD prophylaxis ) past year Subject underwent allogeneic stem cell transplantation least 6 month prior enrollment Subject start new systemic immunosuppressive therapy within 2 week prior enrollment Female subject child bear potential must negative pregnancy test prior first dose tocilizumab must agree practice effective contraception study Subject meet follow medication restriction requirement agree follow medication restriction study ; follow concomitant medication allow : cyclophosphamide , abatacept , etanercept , adalimumab infliximab , golimumab , tofacitinib , alemtuzumab ; medication also use 5 halflives prior enrollment Subject agree comply study requirement agree come clinic require study visit Donor lymphocyte infusion precede 100 day Subject bronchiolitis obliterans , bronchiolitis obliterans organize pneumonia cryptogenic organize pneumonia sole manifestation cGVHD Uncontrolled bacterial , viral infection invasive fungal infection Evidence malignancy within 6 month study enrollment ; define clear morphologic , radiologic molecular evidence disease ; mixed chimerism allow discretion clinician Treatment nonFood Drug Administration ( FDA ) approve agent within 4 week ( 5 halflives investigational drug , whichever long ) study enrollment Immunization live , attenuate vaccine within 4 week prior study enrollment History severe allergic anaphylactic reaction human , humanized murine monoclonal antibody Tuberculosis require treatment within past 3 year ; patient must negative quantiferon test within 4 week prior start study drug Pregnant breastfeed woman Patients ( men woman ) reproductive potential willing use effective method contraception Serum creatinine &gt; 1.6 mg/dL ( 141 umol/L ) females &gt; 1.9 mg/dL ( 168 umol/L ) male ; patient serum creatinine value exceed limit eligible study estimate glomerular filtration rate ( GFR ) &gt; 30 ml/min/1.73 m^2 Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 1.5 time upper limit normal ( ULN ) Total bilirubin &gt; upper limit normal ( ULN ) Absolute neutrophil count &lt; 1.5 x 10^9/L ( 1500/mm^3 ) Known active hepatitis B C ; patient must negative test hepatitis B surface antigen , hepatitis B core antibody hepatitis C antibody within 4 week prior start study drug Known uncontrolled cytomegalovirus ( CMV ) polymerase chain reaction ( PCR ) reactivation per institutional standard ; CMV treat stable per institutional standard , patient may enrol ; CMV PCR test within two week prior start study drug History diverticulitis , Crohn 's disease ulcerative colitis History demyelinating disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>